OBJECTIVE-Based on rodent studies, we examined the hypothesis that increased adipose tissue (AT) mass in obesity without an adequate support of vascularization might lead to hypoxia, macrophage infiltration, and inflammation.
B
oth insulin resistance and ␤-cell failure are present in individuals with type 2 diabetes. Insulin resistance is closely linked to adiposity with a central or visceral pattern, providing a greater risk of insulin resistance and metabolic dysfunction. Adipose tissue (AT) serves as an endocrine organ secreting a variety of autocrine, paracrine, and endocrine factors that can produce or prevent insulin resistance (1) . The failure of AT to adequately proliferate and/or differentiate to sequester lipids away from liver, skeletal muscle, and the pancreatic ␤-cell has been proposed as a precursor to type 2 diabetes, broadening the number of potential mechanisms linking obesity to insulin resistance (2) .
The increase in body fat in obesity should be accompanied by an increase in vascularization, in order to provide adequate oxygen and nutrients (3) . In contrast to expectations, obese mice have lower AT capillary density (rarefaction, also known as capillary drop out) and decreased vascular endothelial growth factor (VEGF), the most potent angiogenic factor (4, 5) . Consistent with this model, preclinical studies suggest that obese AT is hypoxic (6) ; however, the hypothesis that AT rarefaction might lead to hypoxia remains untested.
In humans, short-term whole-body hypoxia decreases insulin sensitivity (7) and short-term whole-body hyperoxygenation increases insulin sensitivity (8) . In mice, obesity is associated with lower oxygen partial pressure in subcutaneous and visceral AT (6, 9) . Studies in postsurgical patients support the idea that AT oxygen partial pressure (AT pO 2 ) is lower in obesity (10) .
In vitro hypoxic adipocytes secrete inflammatory molecules such as tumor necrosis factor (TNF) ␣, interleukin (IL)1, IL6, macrophage inflammatory protein (MIP), and plasminogen activator inhibitor-1 (6, 11) . Increased AT inflammation is a feature of obesity and type 2 diabetes (12) . Hypoxic cells secrete chemokines, which attract macrophages, presumably to clear out necrotic cells and tissue (13) . This suggests the hypothesis that the increase in AT macrophage content seen in human obesity (12) might be due to AT hypoxia.
These preclinical and cell culture experiments suggest that hypoxia might play a role in the inflammation and insulin resistance observed in human obesity. To test this hypothesis, we measured subcutaneous abdominal AT oxygenation (AT pO 2 ) in lean and overweight/obese human subjects and related AT pO 2 to the structure and function of AT.
RESEARCH DESIGN AND METHODS
Twenty-one subjects were recruited and screened based on their BMI: lean (20 -25 kg/m 2 ) or overweight/obese (27-35 kg/m 2 ). Recruiting was conducted via newsprint, postcards, and the Pennington Biomedical Research Center (PBRC) webpage. Subjects were excluded if they had significant renal, cardiac, liver, lung, or neurological disease. Hypertension was acceptable if blood pressure was Ͻ140/90 mmHg on medications. Subjects were excluded for prior use of thiazolidinediones or injectable antihyperglycemic medication; drugs known to affect lipid metabolism, energy metabolism, or body weight; alcohol or other drug abuse; and smoking. The protocol was approved by the institutional review board at the PBRC, and all volunteers gave written informed consent.
Body composition was measured by dual-energy X-ray absorptiometry (DEXA) on a Hologic Dual Energy X-ray Absorptiometer in the fan beam mode (QDR 4500; Hologic, Waltham, MA). The coefficient of variation for the measurement of percentage of body fat is 1.7%. Two days prior and during an in-patient stay, participants were fed a standardized diet (50% carbohydrate, 15% protein, and 35% fat). The number of calories to be provided (and consumed) was calculated as 1.3 ϫ basal energy expenditure using HarrisBenedict equation (665.10 ϩ [9.56 ϫ weight in kg] ϩ [1.85 ϫ height in cm] -[4.68 ϫ age in years for female and 66.47 ϩ {13.75 ϫ weight in kg} ϩ {5.0 ϫ height in cm}] -[6.76 ϫ age in years] for male subjects). Measurement of subcutaneous abdominal AT pO 2 and AT temperature. AT pO 2 was measured using a polarographic micro Clark-type electrode, and AT temperature was measured using a thermocouple concomitantly during two distinct procedures. The measurements were done with a single oxygen probe (cat. no. C1), a single temperature probe (cat. no. C8), or a combined oxygen and temperature probe (cat. no. CC1.P1; Integra Life Sciences, Plainsboro, NJ). The probes were connected to an electronic unit (LICOX CMP; brain oxygen-monitoring unit). This unit displays the AT temperature in°C and the AT pO 2 in mmHg (after controlling for the contribution of temperature on AT pO 2 ). After insertion, the system was allowed to equilibrate for 30 min. Recording was stopped when the difference between measurements done at 5-min interval was Ͻ1 mmHg (steady state); values from the last 10 min were averaged (supplementary Fig. 3 [available in an online appendix at http://dx.doi.org/10.2337/db08-1098). All measurements were made supine, on the left side of the abdomen, at one-third the distance between the umbilicus and the superior iliac crest (supplemental Fig. 1 ) and with the skin uncovered at an ambient room temperature of ϳ25°C.
First, we measured AT pO 2 (mmHg) with the probes inserted into a gas-permeable silastic tubing implanted in the subdermal space as described by Hopf (14) and optimized in our laboratory (indirect method, supplemental Fig. 2 ). Second, AT pO 2 was measured using a direct insertion method developed by our laboratory (supplemental Fig. 2B ). After cleaning the skin with povidone-iodine solution and removal of the dried iodine with sterile saline on gauze, a skin wheal was raised with 1% lidocaine. A combined oxygen and temperature probe was inserted through a 3.2-cm-long 14-Ga IV catheter (Medex) to a depth of 1 cm. The values obtained with the two methods were highly correlated (R ϭ 0.64, P Ͻ 0.01; n ϭ 13). However, the second method was less invasive and provided less discomfort to the volunteers. Therefore, after 13 subjects we only used the second method to measure AT pO 2 and AT temperature. All values in this manuscript are from the "direct" measurement technique. Euglycemic-hyperinsulinemic clamp. The clamp was performed as previously described (15) . Briefly, intravenous catheters were inserted in an antecubital vein for infusions and in a vein on the dorsum of the contra-lateral hand for sampling of arterialized blood. After baseline sampling, a primedcontinuous insulin infusion (80 mU/m 2 per min) was continued for 3-4 h. Insulin was infused for at least 1 h after reaching a concentration of glucose ϳ90 mg/dl. Plasma glucose was measured every 5 min and maintained by a variable 20% glucose infusion. The mean rate of exogenous glucose infusion during steady-state (last 30 min) was corrected for changes in glycemia and divided by fat free mass to assess insulin sensitivity. Laboratory measures. The following assays were done on blood drawn after an overnight fast. Glucose was analyzed using a Beckman Coulter DXC 600 Pro (Brea, CA) and insulin via immunoassay on the Siemens Immulite 2000 (Siemens, Los Angeles, CA). AT biopsy. The skin was anesthetized with a mixture of lidocaine (2%) and bupivocaine (0.025%). AT was obtained using a blunt-ended needle designed for liposuction (3-to 4-mm diameter "mercedes" liposuction needle; M.D. Resource, Hayward, CA) and processed at the bedside by washing in 37°C PBS and snap frozen or preserved in 10% formalin for paraffin blocking. The biopsies obtained from the first completed 14 subjects (8 female and 6 male subjects) were used for the following procedures. Short-term AT release of cytokines. As previously described (16), fresh AT was collected into pregassed 37°C medium 199 and minced into 2-to 5-mg fragments and washed over a nylon mesh. Aliquots were incubated for 3 h in medium 199 containing 1% BSA under a 95% O 2 to 5% CO 2 atmosphere in a shaking water bath (60 cycles/min, 37°C).
MIP1␣ (chemokine [C-C motif] ligand 3), VEGF, TNF␣, leptin, IL1␣, and monocyte chemotactic protein-1 were measured in the condition media using the Luminex system (cat. no. HCYT060K03; MIllipore). The conditioned media was assayed for lactate dehydrogenase and confirmed the absence of cell lysis. Of 14 subjects, 1 subject had no biopsy tissue for the assay (because of technical limitations) and 1 subject had the assay compromised during processing and therefore could not be used. Subsequently, cytokine release was measured in 12 subjects (5 lean and 7 overweight/obese, from which 5 were male and 7 were female). Conditioned media concentrations of VEGF, TNF␣, and leptin were below the detection level of the assay (data not shown). Capillary density. The tissue was cleaned in PBS, fixed in 10% formalin, and embedded in paraffin. Before staining, 3-m sections were deparaffinized and dehydrated by incubation in Xylene (cat. no 247642; Sigma-Aldrich, MO) for 20 min followed by incubation with 100, 90, 80, 70, and 60% ethanol. Slides were rinsed with PBS (20 min). The sections were incubated for 30 min in a dark moist container with the staining solution containing lectin fluorescein isothiocyanate (FITC) conjugate (from Griffonia simplicifolia [GS]) 25 g/ml (cat. no. L2895; Sigma-Aldrich), lectin tetramethylrhodamine isothiocyanate conjugate (from Ulex europaeus [UAE]), 10 g/ml (cat. no. L4889; SigmaAldrich), and 4Ј,6-diamidino-2-phenylindole, dihydrochloride (DAPI) 0.3 (cat. no. D9564; Sigma-Aldrich). The GS lectin stains the plasmalemma, UEA stains the capillaries (17) , and DAPI stains nuclei (18) . In a preliminary experiment, the AT sections were stained with DAPI in addition to GS lectin and UEA lectin, showing that UEA lectin does not stain nuclei (supplemental Fig. 4 ). The sections were rinsed with PBS (40 min) and then mounted on microscope slides with a water-soluble mounting medium (cat. no. M7644-1; Cardinal Health). Images of the stained sections were taken with a Zeiss Axioplan 2 upright microscope (Intelligent Imaging Innovations) using Zeiss Axioplan 2 with a Photometrics CoolSnap HQ CCD camera and a Sutter Lambda LS 175W Xenon arc lamp. A planar Apochromat 20ϫ/0.75 objective lens, three filter sets (DAPI-EX 360/40, FITC-EX HQ487/25, and CY3-EX HQ535/50) and Slidebook Software version 2.0 were used for image capture. Microvessels were counted using MBF ImageJ Bundle software. Microvessel density was expressed as the number of microvessels per millimeter of section area, averaged across 6 -10 images acquired from each section. Quantitative RT-PCR. Human total RNA from ϳ100 mg AT was isolated by column purification (Qiagen). All primers and probes were designed using Primer Express version 2.1 (Applied Biosystems). Sequences of primers and probes are shown in a supplementary table. Leptin and GLUT1 were from ABI (cat. no. Hs00174877_m1, Hs00197884_m1). GLUT1 mRNA was not detectable in the AT samples. Real-time quantitative RT-PCRs (qRT-PCRs) (19) were performed as one-step reactions in ABI PRISM 7900 (Applied Biosystems) using the following parameters: one cycle of 48°C for 30 min, then 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. The relative standard curve method was used to calculate the quantity of the target gene for each tissue extract with an internal control. The "housekeeping gene" cyclophilin B was previously demonstrated to be "stable" across lean and obese subjects (20 -22) . Therefore, each sample value was divided by the quantity of cyclophilin B as previously described (20 -23) . Adipocyte size. Mean adipocyte size was measured as previously described (24) . Tissue was fixed in osmium tetroxide. Dissociation and digestion of proteins was performed with 8 mol/l urea/NaCl. Cells were filtered over a 10-m nylon screen then recollected in a Triton X-100 solution. Approximately 2,500 cells from each sample were analyzed on a Coulter Counter using a 400-m aperture. Statistical methods. Comparison between the lean and overweight/obese subjects was performed using an unpaired t test. Statistical significance was defined relative to a nominal two-sided 5% type-1 error rate. Values are presented as means Ϯ SD. All analyses were performed in JMP (version 5.0.1; SAS, Cary, NC).
RESULTS
Subject characteristics. Subject characteristics are listed in Table 1 . The subjects were men (n ϭ 11) and women (n ϭ 10) with diverse ethnicity: Caucasian (n ϭ 10), African American (n ϭ 10), or Chinese (n ϭ 1). The lean subjects were matched for age with the overweight/ obese subjects without diabetes; however, both goups were younger than the overweight/obese subjects with diabetes (P Ͻ 0.05). Waist circumference was significantly larger in the overweight/obese versus lean group (P Ͻ 0.05). The range of BMI was 20.4 -23.8 kg/m 2 in the lean group and 28.9 -34.7 kg/m 2 in the overweight/obese group. By design, the overweight/obese group had greater BMI compared with the lean group (P Ͻ 0.05) and greater percent fat (P Ͻ 0.05). As expected, overweight/obese subjects had lower insulin sensitivity, as shown by the glucose disposal rates compared with lean subjects (P Ͻ 0.05).
Overweight/obese subjects have lower AT pO 2 and AT temperature without activation of hypoxia target genes. We observed lower AT pO 2 in overweight/obese than lean subjects (range 29.1-62.8 vs. 40.5-73.8 mmHg; P Ͻ 0.05) ( Fig. 1A ; Table 1 ). In addition, AT pO 2 was negatively correlated with percent fat (R ϭ Ϫ0.50, P Ͻ 0.05) (Fig. 1B) and fat mass (R ϭ Ϫ0.48, P Ͻ 0.05). AT temperature was lower in overweight/obese than lean subjects (P Ͻ 0.05) ( Table 1 ) and was negatively correlated with percent body fat (R ϭ Ϫ0.62, P Ͻ 0.01) (Fig. 1C ) Race, sex, and age were not significant contributors to AT pO 2 or AT temperature (P ϭ NS). There was no relationship between the use of antihypertensive medication and AT pO 2 (P ϭ NS).
The differences in AT pO 2 cannot be explained by differences in AT temperature. A 6°C difference in temperature leads to a 1-mmHg difference in pO 2 at atmospheric pressure (suplemental Fig. 3B ), a value that is trivial compared with the range of values for AT pO 2 (ϳ35 mmHg). Next, we measured the expression of known HIF-1 targets: pyruvate dehydrogenase kinase (PDK) 1 and VEGF. We found that PDK1 and VEGF were not upregulated in overweight/obese subjects ( Table 2 ), suggesting that the decrease in AT pO 2 is not sufficient to activate the hypoxia pathway that would increase AT pO 2 to normal values.
Within the overweight/obese group, there were six overweight/obese subjects without type 2 diabetes and six overweight/obese subjects with type 2 diabetes. The groups had similar BMI and insulin sensitivity, and we found similar AT pO 2 and AT temperature. Data in humans suggests that whole-body hypoxia might cause insulin resistance (7, 8) ; however, the relationship with AT pO 2 has not been explored. We found that AT pO 2 did not correlate with glucose disposal rate, a gold-standard measure of skeletal muscle insulin resistance (R ϭ 0.21, P ϭ NS). Evidence for rarefaction in overweight/obese AT. AT pO 2 could be reduced via several potential mechanisms: increased demand for oxygen, decreased blood flow due to vasoconstriction, or decreased blood flow due to rarefaction. To explore the latter possibility, we measured capillary density in AT samples collected from the contra lateral abdomen. Capillary density in AT was reduced by 44% in overweight/obese subjects compared with lean subjects (172 Ϯ 60 vs. 308 Ϯ 135, P Ͻ 0.05) (Fig. 2C) . We found that VEGF mRNA was 58% lower in overweight/ obese versus lean subjects (P Ͻ 0.05) (Fig. 2D) . Capillary density and VEGF expression were strongly correlated (R ϭ 0.81, P Ͻ 0.01) (Fig. 2E) . AT pO 2 was also positively correlated with VEGF mRNA (R ϭ 0.54, P Ͻ 0.05). Total body fat (%) was negatively correlated with capillary density (R ϭ Ϫ0.69, P Ͻ 0.01) and VEGF mRNA (R ϭ Ϫ0.78, P Ͻ 0.01) (Fig. 2F) . To determine the effect of sex, we used capillary density as the dependent variable and percent fat and sex as the independent variables. The effect of sex on capillary density was not significant (data not shown).
Classically, peroxisome proliferator-activated receptor (PPAR)␥ is known as a nuclear hormone receptor that increases adipogenesis and turns on lipogenesis (25) . However, recent evidence strongly suggests that PPAR␥ also drives angiogenesis (26 -28) . We found that PPAR␥1 was strongly correlated with VEGF (R ϭ 0.94, P Ͻ 0.01) (Fig. 2G ) and capillary density (R ϭ 0.72, P Ͻ 0.01). Ultimately, PPAR␥1 was correlated with AT pO 2 (R ϭ 0.60, P Ͻ 0.05).
Angiopoetin 1 (ANG1) is involved in vascular remodeling and is negatively correlated with the rate of body weight change in animals (4,29). We found that ANG1 negatively correlated with AT pO 2 (R ϭ Ϫ0.57, P Ͻ 0.05) and positively with percent fat (R ϭ 0.73, P Ͻ 0.05). These suggest that overweight/obese subjects with lower AT pO 2 have less vascular remodeling compared with lean subjects. Overweight/obese subjects also had a 66% greater expression of collagen VI (collagen VI ␣3 subunit [COL6]), a extracellular matrix collagen (P Ͻ 0.05, Table 2 ). Expression of COL6 was positively correlated with percent body fat (R ϭ 0.55, P Ͻ 0.05) and inversely correlated with AT pO 2 (R ϭ Ϫ0.81, P Ͻ 0.01) Fig. 2H ). In addition to increased AT mass, overweight/obese subjects had greater mean adipocyte size compared with lean subjects (0.86 Ϯ 0.2 vs. 0.43 Ϯ 0.13 l, P Ͻ 0.05). Mean adipocyte size was negatively correlated with capillary density (R ϭ Ϫ0.66, P Ͻ 0.01) and VEGF (R ϭ Ϫ0.69, P Ͻ 0.01). AT pO 2 and AT inflammation. Based on in vitro studies in cultured adipocytes (6,11), we hypothesized that lower AT pO 2 might lead to macrophage recruitment and the secretion of inflammatory cytokines. We have previously validated the use of macrophage-associated antigen [MAC2]/CD163 and CD68 as markers of AT macrophage infiltration (R 2 ϭ 0.77, P Ͻ 0.001) (B. Kozak, J. Gimble, S.R. Smith, unpublished data). Both MAC2/CD163 and CD68 were inversely correlated with AT pO 2 ( Fig. 3A and B ; R ϭ Ϫ0.66, P Ͻ 0.05 and R ϭ Ϫ0.51, P ϭ NS) consistent with accumulation of macrophages in AT with reduced oxygenation. Furthermore, MIP1␣ was higher in the overweight/ obese subjects (Table 2 ) and AT pO 2 was inversely correlated with MIP1␣ expression (R ϭ Ϫ0.41, P ϭ NS) (Fig. 3C ) and MIP1␣ secretion in the media (R ϭ Ϫ0.79, P Ͻ 0.05) (Fig. 3D ). There was a trend toward higher monocyte chemotactic protein-1 and IL1␣ in obesity and negative correlations with AT pO 2 , but these did not reach statistical significance. However, IL1␣ secretion was negatively correlated with VEGF mRNA (R ϭ Ϫ0.70, P Ͻ 0.001) and capillary density (R ϭ Ϫ0.61, P Ͻ 0.05). 
DISCUSSION
Trayhurn and Wood (30) first hypothesized that hypoxia of AT might play a role in insulin resistance. This hypothesis was based on experiments demonstrating that surrogate markers of hypoxia were increased in the AT of obese animals (30) . We found that reduced AT pO 2 in overweight/obese subjects and AT pO 2 strongly correlates with percent body fat. We also found a significant reduction in AT temperature in overweight/obese subjects and a strong inverse correlation with percent total fat. This is in accordance with previous findings (31) showing a lower skin temperature in obesity. The presence of capillary rarefaction suggests that decreased AT perfusion might also play a role. Indeed, there is evidence to suggest that obese subjects have lower blood flow in abdominal adipose subcutaneous tissue (32) . Further work using direct measures of both AT pO 2 and direct measures of AT blood flow such as xenon washout are needed to formally address this hypothesis. There is additional evidence that obese mice have decreased oxygenation in epididymal and retroperitoneal AT (6, 9) and that weight loss increases oxygenation (6). Choban et al. (33) observed an increased incidence of postsurgical wound infections in obese patients. This same group, measuring AT pO 2 in the upper arm, subsequently showed that decreased oxygenation of AT contributes to the increased risk of infection (34) . AT mass and adipocyte hypertrophy are closely related to the metabolic complications of obesity (35) . In vivo data suggested a role for hypoxia in insulin resistance even though AT pO 2 has never been measured in human subjects (7, 8) .
We were unable to demonstrate a correlation between insulin sensitivity and AT pO 2 . A lack of correlation of AT pO 2 and insulin sensitivity may be due to lack of power because this AT pO 2 and inflammation are just two of many factors that induce insulin resistance or perhaps because there is simply no meaningful biological relationship. The correlation between macrophage content and insulin resistance is modest (36) . One limitation of our study is that only one region of the body was measured and only at one depth. Most hypoxic tissues develop strong transcriptional, metabolic, and secretory responses to reduced oxygenation in order to increase capillary density and to correct the hypoxia. Hypoxia turns on genes that act to increase oxygen availability by decreasing oxygen consumption (switching "on" anaerobic glycolysis) and stimulating angiogenesis. Hypoxia target genes expressed in AT include PDK1 and VEGF (37) . Consistent with this data, VEGF and PDK1 are upregulated in adipocytes cultured in 1% oxygen (a hypoxic environment) (6, 9, 11) . In contrast to our expectations, we found that lower AT pO 2 in overweight/ obese subjects did not induce an increase in hypoxia targets (PDK1, VEGF). Also, capillary density and VEGF were decreased in overweight/obese AT along with a lower AT pO 2 . This suggests that the transcriptional counterregulatory system was not activated. One should note, however, that the lowest value of AT pO 2 in the overweight/obese group was 29 mmHg; this corresponds to 3.8% oxygen compared with the 1% oxygen used in the cell culture experiments. This suggests that overweight/obese subjects have low AT pO 2 but not low enough to mount a counterregulatory response driven during a response to hypoxia. Consistent to our results, Lijnen et al. (5) found that obese mice have both lower VEGF and lower vascular density in AT. In addition, it is known that spleen, thymus, and retina have low pO 2 in normal rats (38) , suggesting that angiogenesis is activated at different levels of oxygenation for different types of tissue or that oxygenation could influence angiogenesis. One limitation of our study is that we did not measure VEGF protein, and this should be addressed in future experiments. Recent data suggests that PPAR␥1 might be required for angiogenesis in AT (39) . PPAR␥ drives VEGF (and angiogenesis) (26 -28) . We found a strong positive correlation between PPAR␥1 and VEGF and between VEGF and AT pO 2 . One way to interpret this data is that PPAR␥1 drives angiogenesis in human AT and therefore is a key controller of AT pO 2 . More work is needed to test this hypothesis.
AT expansion (adipogenesis) during development is preceded by a wave of neovascularization (40) . Vascular plasticity may play a role in the ability of AT to increase or decrease in size (29, 41) . Our data suggests that reduced capillary density might restrict the growth of AT. Our finding of reduced capillary density in subcutaneous AT in obesity suggests the hypothesis that the failure of the vasculature to expand with increasing subcutaneous obesity might limit adipogenesis in subcutaneous depot. If visceral AT were not similarly restricted, this might allow for the growth of visceral AT. Further work measuring AT pO 2 and capillary density in omental and mesenteric AT is needed to test this hypothesis.
Previous studies have shown that COL6 is abundantly expressed by adipocytes (42) , and obese mice have increased COL6 expression in the extracellular matrix (43) . We found that overweight/obese subjects with low AT pO 2 have greater expression of COL6, and COL6 expression increased with increased body fat and fat-cell size. Scherer et al. (44) suggests that proteolytic fragments of COL6 promote tumor growth through prosurvival and proliferation signaling pathways such as Akt and ␤-catenin. This suggests that new blood vessel formation is restricted by increased extracellular matrix or that a reduction in angiogenesis leads to increases in the formation of the extracellular matrix as exemplified by COL6. Further work is needed to separate these two possibilities.
AT inflammation has received much attention as an important factor in insulin resistance and type 2 diabetes (6, 12, 45) . Previous in vitro and in vivo preclinical studies showed that hypoxia induces inflammation that might contribute to insulin resistance (6, 11) . We found that in humans, AT pO 2 correlates with macrophage markers (CD68 and MAC2/CD163). In addition, AT secretion of MIP1␣, a potent macrophage chemokine (46, 47) , increased as AT pO 2 decreased. This is consistent with recent data showing upregulation of MIP1␣ in obesity (48) . This is supportive of the hypothesis that lower oxygenation drives inflammation by upregulating adipocyte chemokine secretion but, as discussed previously, not by activating the classic hypoxia pathway and VEGF. However, it is possible that inflammation could drive hypoxia. Given that MIP1␣ has been implicated in angiogenesis, it is unclear why MIP1␣ is up when capillary density is down. Further work is needed to understand the factors regulating angiogenesis in human AT.
In summary, we provide direct evidence of lower AT pO 2 in overweight/obese subjects and that the most likely causes are decreased capillary density and reduced expression of the angiogenic factors like VEGF and PPAR␥1 and increased expression of COL6. This suggests that low AT pO 2 in overweight/obese subjects does not result in a complete counterregulatory response to reduced AT pO 2 and that neovascularization is not activated. Decreased AT pO 2 was paralleled by an increase in the expression and secretion of the chemokine and markers of macrophage infiltration. These data suggests that proangiogenic therapies might reduce AT inflammation, improve insulin action, and reduce cardiovascular disease risk in obesity and type 2 diabetes. 
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